Foamix Pharmaceuticals Ltd News Releases http://investors.foamix.com/ Foamix Pharmaceuticals Ltd News Releases en Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology http://investors.foamix.com/news-releases/news-release-details/foamix-announces-publication-phase-3-fmx101-acne-study-journal REHOVOT, Israel and BRIDGEWATER, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical-stage pharmaceutical company that specializes in developing and commercializing proprietary topical therapies for dermatological conditions, announced today the peer Tue, 04 Jun 2019 08:00:00 -0400 Foamix Pharmaceuticals Ltd News Releases 9096 Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update http://investors.foamix.com/news-releases/news-release-details/foamix-reports-first-quarter-2019-financial-results-and-provides FDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date Conference Call Scheduled for  Wednesday May 8 th at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , May 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the Tue, 07 May 2019 16:21:00 -0400 Foamix Pharmaceuticals Ltd News Releases 9056 Foamix Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019 http://investors.foamix.com/news-releases/news-release-details/foamix-pharmaceuticals-present-bank-america-merrill-lynch-health REHOVOT, Israel , and BRIDGEWATER, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced Mon, 06 May 2019 08:00:00 -0400 Foamix Pharmaceuticals Ltd News Releases 9041 Foamix to Present Late Breaking Data at the 77th Annual Meeting of the Society for Investigative Dermatology http://investors.foamix.com/news-releases/news-release-details/foamix-present-late-breaking-data-77th-annual-meeting-society REHOVOT, Israel and BRIDGEWATER, N.J. , April 29, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in Mon, 29 Apr 2019 08:00:00 -0400 Foamix Pharmaceuticals Ltd News Releases 9036 Foamix Pharmaceuticals First Quarter 2019 Financial Results Conference Call & Webcast Scheduled for May 8 http://investors.foamix.com/news-releases/news-release-details/foamix-pharmaceuticals-first-quarter-2019-financial-results REHOVOT, Israel and BRIDGEWATER, N.J. , April 24, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today Wed, 24 Apr 2019 08:00:00 -0400 Foamix Pharmaceuticals Ltd News Releases 9026 Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam http://investors.foamix.com/news-releases/news-release-details/foamix-announces-settlement-litigation-perrigo-relating-finacea REHOVOT, Israel and BRIDGEWATER, N.J. , April 02, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in Tue, 02 Apr 2019 08:00:00 -0400 Foamix Pharmaceuticals Ltd News Releases 8996 Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019 http://investors.foamix.com/news-releases/news-release-details/foamix-pharmaceuticals-present-barclays-global-healthcare-0 REHOVOT, Israel and BRIDGEWATER, N.J. , March 08, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, Fri, 08 Mar 2019 08:00:00 -0500 Foamix Pharmaceuticals Ltd News Releases 8976 Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne http://investors.foamix.com/news-releases/news-release-details/foamix-announces-fda-acceptance-new-drug-application-fmx101 PDUFA Target Action Date of October 20th, 2019 REHOVOT, Israel , and BRIDGEWATER, N.J. , March 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to Thu, 07 Mar 2019 08:00:00 -0500 Foamix Pharmaceuticals Ltd News Releases 8966 Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference http://investors.foamix.com/news-releases/news-release-details/foamix-pharmaceuticals-present-cowen-company-39th-annual-health REHOVOT, Israel and BRIDGEWATER, N.J. , March 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, Wed, 06 Mar 2019 08:00:00 -0500 Foamix Pharmaceuticals Ltd News Releases 8951 Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update http://investors.foamix.com/news-releases/news-release-details/foamix-reports-fiscal-year-2018-financial-results-and-provides Conference Call Scheduled for Friday, March 1 at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on Thu, 28 Feb 2019 16:01:00 -0500 Foamix Pharmaceuticals Ltd News Releases 8926